This puts Spark in the vanguard of gene and cell therapy, and if approved by the FDA, it will be the first ever gene therapy for a genetic disease to reach the US market.

However, the lack of a clear timeline ... with its ctLNP (cell-targeted lipid nanoparticle) platform. Recent presentations at the European Society of Gene and Cell Therapy (ESGCT) and the American ...

Global Scientific Director, Flow Cytometry and Targeted Cell Isolation, Labcorp Watch the second of a three-part roundtable series that focus on approaches to accelerating your advanced therapy ...